Title: Septra - FDA prescribing information, side effects and uses
Headings: Septra
Septra
On This Page
Septra Description
Septra - Clinical Pharmacology
Geriatric Pharmacokinetics:
Microbiology:
Susceptibility Testing:
Indications and Usage for Septra
Urinary Tract Infections:
Acute Otitis Media:
Acute Exacerbations of Chronic Bronchitis in Adults:
Travelers' Diarrhea in Adults:
Shigellosis:
Pneumocystis Carinii Pneumonia:
Contraindications
Warnings
Adjunctive Treatment with Leucovorin for Pneumocystis jiroveci pneumonia
Precautions
General
Use in the Elderly:
Use in the Treatment of and Prophylaxis for Pneumocystis carinii Pneumonia in Patients with Acquired Immunodeficiency Syndrome (AIDS):
Information for Patients:
Laboratory Tests:
Drug Interactions:
Drug/Laboratory Test Interactions:
Carcinogenesis, Mutagenesis, Impairment of Fertility:
Pregnancy
Teratogenic Effects:
Nonteratogenic Effects:
Nursing Mothers:
Pediatric Use:
Geriatric Use:
Adverse Reactions
Hematologic:
Allergic:
Gastrointestinal:
Genitourinary:
Metabolic:
Neurologic:
Psychiatric:
Endocrine:
Musculoskeletal:
Respiratory System:
Miscellaneous:
Overdosage
Acute:
Chronic:
Septra Dosage and Administration
Urinary Tract Infections and Shigellosis in Adults and Pediatric Patients and Acute Otitis Media in Pediatric Patients:
Acute Exacerbations of Chronic Bronchitis in Adults:
Travelers' Diarrhea in Adults:
Pneumocystis Carinii Pneumonia:
Treatment:
Prophylaxis:
How is Septra Supplied
REFERENCES
PRINCIPAL DISPLAY PANEL - 100 Tablet Bottle Label
100 Tablets
PRINCIPAL DISPLAY PANEL - 20 Tablet Bottle Label
PRINCIPAL DISPLAY PANEL - 100 Tablet Bottle Label
100 Tablets
PRINCIPAL DISPLAY PANEL - 500 Tablet Bottle Label
Frequently asked questions
More about Septra (sulfamethoxazole / trimethoprim)
Consumer resources
Professional resources
Other brands
Other Formulations
Related treatment guides

Content: The usual spectrum of antimicrobial activity of Septra includes bacterial pathogens isolated from middle ear exudate and from bronchial secretions ( Haemophilus influenzae, including ampicillin-resistant strains, and Streptococcus pneumoniae ), and enterotoxigenic strains of Escherichia coli (ETEC) causing bacterial gastroenteritis. Shigella flexneri and Shigella sonnei are also usually susceptible. REPRESENTATIVE MINIMUM INHIBITORY CONCENTRATION VALUES FOR ORGANISMS SUSCEPTIBLE TO Septra (MICμg/mL)

TMP/SMX (1:19)

TMP
SMX


Bacteria
Alone
Alone
TMP
SMX
Escherichia coli
0.05-1.5
1.0-245
0.05-0.5
0.95-9.5
Escherichia coli (enterotoxigenic strains)
0.015-0.15
0.285->950
0.005-0.15
0.095-2.85
Proteus species (indole positive)
0.5-5.0
7.35-300
0.05-1.5
0.95-28.5



TMP/SMX (1:19)

TMP
SMX


Bacteria
Alone
Alone
TMP
SMX
Morganella morganii
0.5-5.0
7.35-300
0.05-1.5
0.95-28.5
Proteus mirabilis
0.5-1.5
7.35-30
0.05-0.15
0.95-2.85
Klebsiella species
0.15-5.0
2.45-245
0.05-1.5
0.95-28.5
Enterobacter species
0.15-5.0
2.45-245
0.05-1.5
0.95-28.5
Haemophilus influenzae
0.15-1.5
2.85-95
0.015-0.15
0.285-2.85



TMP/SMX (1:19)

TMP
SMX


Bacteria
Alone
Alone
TMP
SMX
Streptococcus pneumoniae
0.15-1.5
7.35-24.5
0.05-0.15
0.95-2.85
Shigella flexneri*
<0.01-0.04
<0.16->320
<0.002-0.03
0.04-0.625
Shigella sonnei*
0.02-0.08
0.625->320
0.004-0.06
0.08-1.25
TMP=trimethoprim
SMX=sulfamethoxazole
*Rudoy RC, Nelson JD, Haltalin KC. Antimicrobial Agents and Chemotherapy. 1974;5:439-443. Susceptibility Testing: The recommended quantitative disc susceptibility method may be used for estimating the susceptibility of bacteria to Septra. 4,5 With this procedure, a report from the laboratory of "Susceptible to trimethoprim and sulfamethoxazole" indicates that the infection is likely to respond to therapy with Septra. If the infection is confined to the urine, a report of "Intermediate susceptibility to trimethoprim and sulfamethoxazole" also indicates that the infection is likely to respond. A report of "Resistant to trimethoprim and sulfamethoxazole" indicates that the infection is unlikely to respond to therapy with Septra.